Necroptosis is a programmed form of necrosis, and is an alternative mode of regulated cell death mimicking features of apoptosis and necrosis.
Generally, cell demise and its survival are the fundamental features of metazoans to maintain the tissue homeostasis. On morphological basis, cell death is achieved by apoptosis, necrosis, and autophagy.
A plenty of studies has been performed on apoptosis and autophagy and reveals a clear picture of molecular mechanisms of apoptosis and autophagy which is recognized as a highly regulated process. Hence, apoptosis and autophagy are usually regarded as “programmed cell death”, but necrosis is considered as “un-programmed” due to deregulated activity.
Necroptosis is specific to vertebrates and may have originated as an additional defense to pathogens. Necroptosis also acts as an alternative "fail-safe" cell death pathway in cases where cells are unable to undergo apoptosis, such as during viral infection in which apoptosis signaling proteins are blocked by the virus.
Additionally, recent studies implicate it in a variety of disease states. In myocardial infarction and stroke, atherosclerosis, ischemia-reperfusion injury, pancreatitis, inflammatory bowel disease and a number of other clinically common disorders, necroptosis is of central pathophysiological relevance.
Necroptosis is a newly discovered pathway of regulated necrosis. It can be initiated by different stimuli, such as tumor necrosis factor (TNF), TNF-related apoptosis-inducing ligand (TRAIL), Fas ligand (FasL), interferon (IFN), LPS, viral DNA or RNA, DNA-damage agent and requires the kinase activity of receptor-interacting protein 1 (RIPK1) and RIPK3.
RIPK1 has important kinase-dependent and scaffolding functions that inhibit or trigger necroptosis and apoptosis. Its execution involves ROS generation, calcium overload, the opening of the mitochondrial permeability transition pore, mitochondrial fission, inflammatory response and chromatinolysis. Necroptosis participates in many pathogenesis of diseases, including neurological diseases, retinal disorders, acute kidney injury, inflammatory diseases and microbial infections.
|JAK2||JAK2 Antibody||JAK2 Protein||JAK2 cDNA||JAK2 ELISA Kit|
|JAK3||JAK3 Antibody||JAK3 Protein||JAK3 cDNA||JAK3 ELISA Kit|
|MAPK10||MAPK10 Antibody||MAPK10 Protein||MAPK10 cDNA||MAPK10 ELISA Kit|
|MAPK8||MAPK8 Antibody||MAPK8 Protein||MAPK8 cDNA||MAPK8 ELISA Kit|
|MAPK9||MAPK9 Antibody||MAPK9 Protein||MAPK9 cDNA||MAPK9 ELISA Kit|
|MLKL||MLKL Antibody||MLKL Protein||MLKL cDNA||MLKL ELISA Kit|
|NLRP3||NLRP3 Antibody||NLRP3 Protein||NLRP3 cDNA||NLRP3 ELISA Kit|
|PARP1||PARP1 Antibody||PARP1 Protein||PARP1 cDNA||PARP1 ELISA Kit|
|PARP2||PARP2 Antibody||PARP2 Protein||PARP2 cDNA||PARP2 ELISA Kit|
|PARP3||PARP3 Antibody||PARP3 Protein||PARP3 cDNA||PARP3 ELISA Kit|
|PARP4||PARP4 Antibody||PARP4 Protein||PARP4 cDNA||PARP4 ELISA Kit|
|PGAM5||PGAM5 Antibody||PGAM5 Protein||PGAM5 cDNA||PGAM5 ELISA Kit|
|PLA2G4A||PLA2G4A Antibody||PLA2G4A Protein||PLA2G4A cDNA||PLA2G4A ELISA Kit|
|PLA2G4C||PLA2G4C Antibody||PLA2G4C Protein||PLA2G4C cDNA||PLA2G4C ELISA Kit|
|PLA2G4D||PLA2G4D Antibody||PLA2G4D Protein||PLA2G4D cDNA||PLA2G4D ELISA Kit|
|PLA2G4E||PLA2G4E Antibody||PLA2G4E Protein||PLA2G4E cDNA||PLA2G4E ELISA Kit|
|PLA2G4F||PLA2G4F Antibody||PLA2G4F Protein||PLA2G4F cDNA||PLA2G4F ELISA Kit|
|PPIA||PPIA Antibody||PPIA Protein||PPIA cDNA||PPIA ELISA Kit|
|PPID||PPID Antibody||PPID Protein||PPID cDNA||PPID ELISA Kit|
|PYCARD||PYCARD Antibody||PYCARD Protein||PYCARD cDNA||PYCARD ELISA Kit|